Russian Drug for Coronavirus "Favipiravir" Received Permanent Registration
OREANDA-NEWS. According to the Deputy Minister of Health of the Russian Federation Viktor Fisenko, the Russian drug for the treatment of COVID-19 "Favipiravir" has received official permanent registration, after all the conditions for temporary registration have already been met.
In September, the Russian Ministry of Health authorized the outpatient use of two domestic drugs for coronavirus disease with the international non-proprietary name Favipiravir - Coronavir, produced by company R-Pharm and Areplivir, developed by Promomed company. Previously, they were used exclusively for the treatment of patients in hospitals.
The Deputy Minister of Health clarified that at the moment they have already completed a number of positions, in particular on Favipiravir, implemented and fulfilled the conditions for 441 resolutions, and, accordingly, this medicine received a permanent registration certificate.
Moreover, Favipiravir was recently added to the list of essential drugs. On October 16, a ceiling price was set for this medicine - 5,500 rubles without any regional markups.
In total, during the pandemic in Russia, more than one and a half million cases of coronavirus were detected, over 26 thousand people died, 1.16 million recovered.